Antimicrobials therapy of anaerobic infections

Journal of Chemotherapy

Volumn 28, Issue 3, 2016, Pages 143-150

  Brook, Itzhak ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaerobes; Antibiotics; Antimicrobial resistance; Bacteroides fragilis

Indexed keywords

AMOXICILLIN; AMPICILLIN; BACITRACIN; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CARBENICILLIN; CEFOTETAN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TICARCILLIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANAEROBIC INFECTION; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; APLASTIC ANEMIA; ARTICLE; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES VULGATUS; BRAIN TOXICITY; CLOSTRIDIUM; DIARRHEA; DRUG FEVER; FUSOBACTERIUM; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE ANAEROBIC COCCI; HEMOLYTIC ANEMIA; HUMAN; METALLIC TASTE; MIXED INFECTION; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; PARABACTEROIDES DISTASONIS; PERIPHERAL NEUROPATHY; PHLEBITIS; PREVOTELLA; VOMITING; ANAEROBIC BACTERIUM; BACTERIAL INFECTIONS; DRUG EFFECTS;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; HUMANS;

EID: 84978730655     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947815Y.0000000068     Document Type: Article

References (79)

1. D.J.Hentges. The anaerobic microflora of the human body. Clin Infect Dis. 1993;16(4):S175–80.
2. I.Brook. Anaerobic infections diagnosis and management. New York: Informa Healthcare USA, Inc; 2007.
3. S.M.Finegold. Anaerobic bacteria in human disease. New York: Academic Press; 1977.
4. H.R.Jousimies-Somer, P.Summanen, D.M.Citron, E.J.Baron, H.M.Wexler, S.M.Finegold. Wadsworth-KTL anaerobic bacteriology manual. 6th edn. Belmont, CA: Star Publishing; 2002.
5. E.Nagy. Anaerobic infections: update on treatment considerations. Drugs. 2010;70(5):841–58.
6. D.M.Citron, D.W.Hecht. Susceptibility test methods: anaerobic bacteria. In: J.Versalovic, editor. Manual of clinical microbiology. 10th edn. Washington, DC: American Society for Microbiology Press; 2010; p. 1204–14.
7. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 8th edn. Wayne, PA: Clinical and Laboratory Standards Institute [CLSI Document M11-A9]; 2012.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty second informational supplement. Wayne, PA: CLSI [CLSI Document M100-S22]; 2012.
9. D.M.Citron, E.J.Goldstein, C.V.Merriam, B.A.Lipsky, M.A.Abramson. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45(9):2819–28.
10. E.J.C.Goldstein, D.M.Citron, P.J.Goldman, R.J.Goldman. National survey of anaerobic culture and susceptibility methods: III. Anaerobe. 2008;14(2):68–72.
11. J.E.Sherwood, S.Fraser, D.M.Citron, H.Wexler, G.Blakely, K.Jobling, Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe. 2011;17(4):152–5.
12. D.R.Snydman, N.V.Jacobus, L.A.McDermott, Y.Golan, E.J.Goldstein, L.Harrell, Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe. 2011;17(4):147–51.
13. I.Brook. Antimicrobial treatment of anaerobic infections. Expert Opin Pharmacother. 2011;12:1691–707.
14. H.M.Wexler. Bacteroides - the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20(4):593–621.
15. D.F.Busch, L.A.Kureshi, V.L.Sutter, S.M.Finegold. Susceptibility of respiratory tract anaerobes to orally administered penicillins and cephalosporins. Antimicrob Agents Chemother. 1976;10(6):713–20.
16. C.Acuna, X.Rabasseda. Amoxicillin-sulbactam: a clinical and therapeutic review. Drugs Today (Barc). 2001;37:193–210.
17. S.M.Finegold. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents. 1999;12(Suppl 1):S9–14.
18. J.S.Solomkin, J.E.Mazuski, J.S.Bradley, K.A.Rodvold, E.J.Goldstein, E.J.Baron, Diagnosis and management of complicated intraabdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(1):133–64.
19. D.L.Stevens, A.L.Bisno, H.F.Chambers, E.P.Dellinger, E.J.Goldstein, S.L.Gorbach, Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(8):1373–406.
20. E.J.C.Goldstein, D.M.Citron. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part I and part II. Clin Microbiol Newsletter. 2011;33(1):1–14.
21. E.Strehl, F.Kees. Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use. Drugs. 2000;59(Suppl 3):9–18.
22. V.L.Sutter, S.M.Finegold. Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother. 1976;10:736–52.
23. D.W.Hecht. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis. 2004;39(1):92–7.
24. E.J.C.Goldstein, D.M.Citron, R.E.Cole, D.M.Rangel, A.S.Seid, M.O.Ostovari. Cefoxitin in the treatment of aerobic/anaerobic infections: prospective correlation of in vitro susceptibility methods with clinical outcome. Hosp Pract (Off Ed). 1990;25(Suppl 4):38–45.
25. E.J.C.Goldstein, D.M.Citron, C.V.Merriam, M.A.Abramson. Infections after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surg Infect. 2009;10(1):111–8.
26. K.M.Itani, S.E.Wilson, S.S.Awad, J.E.Tomassini, M.A.Abramson. Ertapenem versus cefotetan prophylaxis in colorectal surgery. N Engl J Med. 2006;355(2):2640–51.
27. J.Solomkin, Y.P.Zhao, E.L.Ma, M.J.Chen, B.Hampel; DRAGON Study Team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents. 2009;34(5):439–45.
28. W.C.Hellinger, N.S.Brewer. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc. 1999;74(3):420–34.
29. K.Aldridge, K.E.Aldridge, D.Ashcraft, C.L.Pierson, S.G.Jenkins, J.E.Rosenblatt. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group. Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother. 2001;45(4):1238–43.
30. D.L.Paterson, D.D.Depestel, Doripenem. Clin Infect Dis. 2009;49(3):291–8.
31. D.P.Nicolau, Y.Carmeli, C.W.Crank, D.A.Goff, C.J.Graber, A.L.Lima, Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012;39(1):11–15.
32. J.H.Jorgensen, L.A.Maher, A.W.Howell. Activity of meropenem against antibiotic-resistant or infrequently encountered Gram-negative bacilli. Antimicrob Agents Chemother. 1991;35(11):2410–4.
33. J.N.Kattan, M.V.Villegas, J.P.Quinn. New developments in carbapenems. Clin Microbiol Infect. 2008;14(12):1102–11.
34. G.M.Keating, C.M.Perry. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs. 2005;65(15):2151–78.
35. C.Y.Liu, Y.T.Huang, C.H.Liao, L.C.Yen, H.Y.Lin, P.R.Hsueh. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother. 2008;52(9):3161–8.
36. H.M.Wexler. Susceptibility testing of anaerobic bacteria: myth, magic, or method? Clin Microbiol Rev. 1991;4(4):470–84.
37. M.S.Helfand, R.A.Bonomo. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens. Curr Opin Pharmacol. 2005;5(5):452–8.
38. P.C.Appelbaum, S.K.Spangler, G.A.Pankuch, A.Philippon, M.R.Jacobs, R.Shiman, Characterization of a beta-lactamase from Clostridium clostridioforme. J Antimicrob Chemother. 1994;33(1):33–40.
39. L.Pumbwe, A.Chang, R.L.Smith, H.M.Wexler. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. J Antimicrob Chemother. 2006;58(3):543–8.
40. D.R.Snydman, N.V.Jacobus, L.A.McDermott, Y.Golan, D.W.Hecht, E.J.Goldstein, Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis. 2010;50(Suppl 1):S26–S33.
41. D.R.Snydman, N.V.Jacobus, L.A.McDermott, S.Supran, G.J.CuchuralJr, S.Finegold, Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother. 1999;43(10):2417–22.
42. D.R.Snydman, N.V.Jacobus, L.A.McDermott, R.Ruthazer, E.J.Goldstein, S.M.Finegold, National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin Infect Dis. 2002;35:S126–34.
43. D.W.Hecht, J.R.Osmolski, J.P.O'Keefe. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis. 1993;16(Suppl 4):S357–60.
44. H.Thadepalli, S.L.Gorbach, J.G.Bartlett. Apparent failure of chloramphenicol in anaerobic infections. Obstet Gynecol Surg. 1978;35(5):334–5.
45. H.J.Balbi. Chloramphenicol: a review. Pediatr Rev. 2004;25(8):284–8.
46. R.Nau, F.Sorgel, H.W.Prange. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet. 1998;35(3):223–46.
47. E.J.C.Goldstein, D.M.Citron, C.V.Merriam. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother. 1999;43(6):1469–74.
48. J.D.Williams, J.P.Maskell, H.Shain, G.Chrysos, A.M.Sefton, H.Y.Fraser. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother. 1992;30(1):27–37.
49. E.J.C.Goldstein, R.P.Lewis, V.L.Sutter, S.M.Finegold. Treatment for anaerobic pleuropulmonary and soft-tissue Infections with erythromycin. JAMA. 1979;242(5):435–8.
50. Y.Sanai, G.R.Persson, J.R.Starr, H.S.Luis, M.Bernardo, J.Leitao, Presence and antibiotic resistance of Porphyromonas gingivalis. Prevotella intermedia, and Prevotella nigrescens in children. J Clin Periodontol. 2002;29(10):929–34.
51. R.D.Feigin, L.K.Pickering, D.Anderson, H.S.Luis, M.Bernardo, J.Leitao, Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics. 1975;55(10):213–23.
52. A.S.Klainer, Clindamycin. Med Clin North Am. 1987;71(6):1169–75.
53. C.M.Paap, M.C.Nahata. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet. 1990;19(4):280–318.
54. J.D.Panzer, D.C.Brown, W.L.Epstein, R.L.Lipson, H.W.Mahaffey, W.H.Atkinson. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol. 1972;12(7):259–62.
55. S.L.Gorbach. Antibiotics and Clostridium difficile. N Engl J Med. 1999;341(22):1690–1.
56. E.Mylonakis, E.T.Ryan, S.B.Calderwood. Clostridium difficile - associated diarrhea: a review. Arch Intern Med. 2001;161(4):525–33.
57. J.S.Solomkin, J.E.Mazuski, J.S.Bradley, K.A.Rodvold, E.J.Goldstein, E.J.Baron, Diagnosis and management of complicated intraabdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt). 2010;11(1):79–109.
58. C.E.Nord, C.Oprica. Antibiotic resistance in Propionibacterium acnes, microbiological and clinical aspects. Anaerobe. 2006;12(2):207–10.
59. A.W.Chow, V.Patten, L.B.Guze. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of non-spore forming Gram-positive bacilli. J Infect Dis. 1975;131(2):182–5.
60. M.Rustia, P.Shubik. Experimental induction of hematomas, mammary tumors and other tumors with metronidazole in noninbred Sas: WRC (WT)BR rats. J Natl Cancer Inst. 1979;63(6):863–8.
61. S.M.Cohen, E.Ertürk, A.M.Von Esch, A.J.Crovetti, G.T.Bryan. Carcinogenicity of 5-nitrofurans, 5-nitroimidazoles, 4-nitrobenzenes, and related compounds. J Natl Cancer Inst. 1973;51(2):403–17.
62. C.M.Beard, K.L.Noller, W.M.O'Fallon, L.T.Kurland, M.B.Dockerty. Lack of evidence for cancer due to use of metronidazole. N Engl J Med. 1979;301(10):519–22.
63. S.Loöfmark, C.Edlund, C.E.Nord. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Inf Dis. 2010;50(Supp. 1):s16–23.
64. I.Brook. Treatment of anaerobic infections in children with metronidazole. Dev Pharmacol. 1983;6(3):187–98.
65. H.T.Sørensen, H.Larsen, E.S.Jensen, A.M.Thulstrup, H.C.Schønheyder, G.L.Nielsen, Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother. 1999;44(6):854–5.
66. E.J.C.Goldstein, D.M.Citron, Y.A.Warren, K.L.Tyrrell, H.T.Fernandez. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother. 2006;50(10):3507–13.
67. N.V.Jacobus, L.A.McDermott, R.Ruthazer, D.R.Snydman. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother. 2004;48(2):1034–6.
68. M.L.Townsend, M.W.Pound, R.H.Drew. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract. 2006;60(12):1662–7.
69. P.C.Appelbaum. Quinolone activity against anaerobes. Drugs. 1999;58(1):60–4.
70. C.E.Edmiston, C.J.Krepel, G.R.Seabrook, L.R.Somberg, A.Nakeeb, R.A.Cambria, In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. 2004;48(3):1012–6.
71. G.E.Stein, E.J.Goldstein. Fluoroquinolones and anaerobes. Clin Infect Dis. 2006;42(11):1598–607.
72. E.J.C.Goldstein, D.M.Citron, Y.A.Warren, K.L.Tyrrell, C.V.Merriam, H.Fernandez. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother. 2006;50(1):148–55.
73. H.Oh, M.Hedberg, C.Edlund. Efflux-mediated fluoroquinolone resistance in the Bacteroides fragilis group. Anaerobe. 2002;8(3):277–82.
74. E.J.C.Goldstein, D.M.Citron, J.Solomkin, J.D.Alder. Clinical efficacy and correlation of clinical outcomes with the in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011;53(11):1074–80.
75. K.L.Tyrrell, D.M.Citron, Y.A.Warren, E.J.Goldstein. In-vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob Agents Chemother. 2012;56(4):2194–7.
76. R.G.Finch. Antibacterial activity of quinupristin/dalfopristin. Ration Clin Use Drugs. 1996;51(1):31–7.
77. J.E.Mazuski, J.S.Solomkin. Intra-abdominal infections. Surg Clin North Am. 2009;89(2):421–37.
78. I.Brook, E.Gober. Emergence of beta-lactamase-producing aerobic and anaerobic bacteria in the oropharynx of children following penicillin chemotherapy. Clin Pediatr. 1984;23(6):338–41.
79. A.Katsandri, J.Papaparaskevas, A.Pantazatou, G.L.Petrikkos, G.Thomopoulos, D.P.Houhoula, Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains. J Clin Microbiol. 2006;44(9):3465–7.